Commentary
Video
The Role of Monoclonal Antibodies and Emerging Combination Treatments to Expand Alzheimer Therapeutics: Howard Fillit, MD
The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation talked about how Alzheimer disease treatment may evolve through combination therapies, adding potential anti-tau and anti-inflammatory agents to improve patient outcomes. [WATCH TIME: 5 minutes]
WATCH TIME: 5 minutes
“The monoclonal antibodies show a 30% slowing of Alzheimer progression, but the goal is to reach 100%—combination therapies could be a step towards this.”
The Alzheimer’s Drug Discovery Foundation (ADDF) recently led a roundtable titled, “Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer’s Treatments,” at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference, held October 29 to November 1, in Madrid, Spain. Moderated by Jeffrey Cummings, MD, ScD, the panel featured Howard Fillit, MD, alongside other Alzheimer disease (AD) experts from industry, academia, and clinical research.1,2
According to ADDF, the panel elaborated upon the recommendations of an expert advisory board, which was convened by the organization earlier this year, that recently offered critical considerations on how to approach and accelerate combination therapy the best in trials for patients with AD. One of the roundtable panelists, Fillit, also chaired a session, titled “Emerging Solutions: Novel Approaches to Treating Alzheimer’s Disease,” which highlighted several promising therapeutic programs that explore the underlying aging pathologies that contribute to the onset of the disease.
Prior to the roundtable, Fillit, the cofounder and chief science officer at the ADDF, sat down with NeurologyLive® to discuss the potential benefits of adding anti-tau and anti-inflammatory agents to existing monoclonal antibody therapies in AD treatment. He also spoke about how trial designs might evolve to accurately assess the impact of these combination therapies. Moreover, Fillit explained the challenges that might be anticipated in integrating anti-inflammatory agents into standard Alzheimer treatments.
Click here for more coverage of CTAD 2024.
